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Inflammasomes are involved in diverse inflammatory
diseases, so the activation of inflammasomes needs
to be tightly controlled to prevent excessive inflam-
mation. However, the endogenous regulatorymecha-
nisms of inflammasome activation are still unclear.
Here, we report that the neurotransmitter dopamine
(DA) inhibits NLRP3 inflammasome activation via
dopamine D1 receptor (DRD1). DRD1 signaling nega-
tively regulates NLRP3 inflammasome via a sec-
ond messenger cyclic adenosine monophosphate
(cAMP), which binds to NLRP3 and promotes its
ubiquitination and degradation via the E3 ubiquitin
ligase MARCH7. Importantly, in vivo data show
thatDAandDRD1signalingpreventNLRP3 inflamma-
some-dependent inflammation, includingneurotoxin-
induced neuroinflammation, LPS-induced systemic
inflammation, and monosodium urate crystal (MSU)-
induced peritoneal inflammation. Taken together,
our results reveal an endogenous mechanism of
inflammasome regulation and suggest DRD1 as a
potential target for the treatment of NLRP3 inflamma-
some-driven diseases.INTRODUCTION
The NLRP3 inflammasome is a cytosolic protein complex
composed of NLRP3, ASC, and caspase-1, and assembled in
response to both microbial infection and endogenous ‘‘danger
signal’’ (Davis et al., 2011; Martinon et al., 2009). The activation
of NLRP3 inflammasome promotes the maturation and release
of several proinflammatory cytokines, such as interleukin-1b
(IL-1b) and IL-18, so it plays critical roles in the initiation of inflam-
mation and the development of immune responses (Lamkanfi
and Dixit, 2012; Schroder and Tschopp, 2010). However, as
excessive and persistent inflammation is quite harmful, NLRP3
inflammasome has been involved in diverse inflammatory dis-
eases, including type 2 diabetes, atherosclerosis, and gout,
thus the activation of NLRP3 inflammasome should be tightly
controlled (Davis et al., 2011; Lamkanfi and Dixit, 2012). Several62 Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc.regulatory mechanisms have been identified to suppress NLRP3
inflammasome. Type I interferon has been shown to attenuate
NLRP3 inflammasome activation via Stat1-dependent manner,
while nitric oxide has been identified as another negative regu-
lator of NLRP3 inflammasome activation (Guarda et al., 2011;
Mishra et al., 2013). Recently, we have proposed that u-3
fatty acids can negatively regulate NLRP3 inflammasome activa-
tion via G protein coupled receptor 120 (GPR120) and GPR40
(Yan et al., 2013). Although NLRP3 inflammasome has been
extensively investigated, its regulatory networks, especially the
endogenous mechanisms, still remain elusive.
Dopamine (DA) is a neurotransmitter, which not only can regu-
late behavior, movement, endocrine, cardiovascular, renal, and
gastrointestinal functions, but also functions as an important
molecule bridging the nervous and immune systems (Basu
and Dasgupta, 2000; Beck et al., 2004; Sarkar et al., 2010).
DA receptors are present in almost all immune cell subpopula-
tions (Sarkar et al., 2010). Acting on its receptors, DA or agonists
for DA receptors have been reported to modulate the activation,
proliferation, and cytokine production in immune cells (Basu and
Dasgupta, 2000; Sarkar et al., 2010; Torres-Rosas et al., 2014).
In addition, dopamine D2 receptor (DRD2) knockout mice show
remarkable inflammatory response in CNS, suggesting that DA
and its downstream signaling has an antiinflammatory function
(Shao et al., 2013). Consistent with this, the deficiency of DA
is tightly associated with immune system abnormalities and
CNS inflammation in the progression of Parkinson disease
(PD) (Perry, 2012; Wu¨llner and Klockgether, 2003). Although
the antiinflammatory effect of DA and its implication in the pa-
thology of PD are emerging, the mechanisms are still poorly
understood.
Here, we demonstrate that DA is an endogenous regulator
of inflammasome activation and suggest the DRD1 as a poten-
tial target for the treatment of NLRP3 inflammasome-driven
diseases.RESULTS
DA Inhibits NLRP3 Inflammasome Activation
To determine the effect of DA on inflammasome activation,
LPS-primed bone marrow-derived macrophages (BMDMs)
were pretreated with DA before nigericin challenge. NLRP3-
dependent caspase-1 activation and IL-1b maturation by
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Figure 1. DA Inhibits NLRP3 Inflammasome Activation
(A) Immunoblot analysis of IL-1b and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with various doses (above
lanes) of DA and then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1b (pro-IL-1b) and caspase-1 (pro-caspase-1) in lysates of those
cells (Input).
(B–D) ELISA of IL-1b (B), IL-18 (C), and TNF-a (D) in supernatants from LPS-primed BMDMs treated for 3 hr with various doses (above lanes) of DA and then
stimulated with nigericin.
(E) Immunoblot analysis of IL-1b and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with DA and then stimulated
with MSU, nigericin, ATP, and Alum, and immunoblot analysis of the precursors of IL-1b (pro-IL-1b) and caspase-1 (pro-caspase-1) in lysates of those cells
(Input).
(F) ELISA of IL-1b in supernatants from LPS-primed BMDMs treated for 3 hr with DA and then stimulated with MSU, nigericin, ATP, and Alum.
Data are means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S1.nigericin were indeed inhibited by DA in a dose-dependent
manner (Figures 1A and 1B and Figure S1A available online).
Similarly, DA also inhibited nigericin-induced production of
IL-18, another NLRP3-inflammasome-dependent cytokine (Fig-
ures 1C and S1B). However, the production of TNF-a, an inflam-
masome-independent cytokine, was not affected by DA in this
condition (Figure 1D), suggesting that DA inhibited IL-1b pro-
duction via affecting inflammasome activation. The physiolog-
ical DA levels found in extracellular fluid surrounding neural
synapses are 1 mM (Basu et al., 2001; Chakroborty et al.,
2008), but in our study, the DA concentration required for in-
flammasome inhibition is over 100 mM, which exceeds the phys-
iological concentration of DA. We speculated that the high DA
concentration needed for inflammasome inhibition might be
due to the instability of DA. Actually, the half-life of DA is
<2 min in plasma and is even much shorter in mouse brain tis-
sues (Rouge-Pont et al., 2002), possibly because dopamine can
be broken down into inactive metabolites by a set of enzymes,
such as monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) (Youdim et al., 2006). To test this possibility,
we changed the DA treatment protocol from one single treat-
ment with high dose to multiple treatments with low dose. The
results showed that one single treatment with 45 mM or 90 mM
DA could not inhibit nigericin-induced IL-1b production, while
treatment with 1.5 mM or 3 mM DA for 30 times (time interval
is 5 min) inhibited nigericin-induced IL-1b production signifi-
cantly, although the total doses were identical (Figure S1C).
Moreover, although DA could not inhibit nigericin-induced IL-
1b production at the doses under 10 mM, it really could suppress
IL-1b production in the presence of MAO and COMT inhibitors
at these doses (Figure S1D). In addition, the DA treatment had
no effect on cell viability (Figure S1E). Taken together, these re-
sults indicate that DA has the potential to inhibit caspase-1 acti-
vation and IL-1b secretion.
To test whether DA only affect nigericin-induced NLRP3 in-
flammasome activation, we examined other NLRP3 agonists.
The results showed that DA could inhibit caspase-1 cleavage
and IL-1b secretion induced by all examined agonists, includingCell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc. 63
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Figure 2. DA Inhibits NLRP3 Inflammasome Activation via DRD1
(A) ELISA of IL-1b in supernatants from LPS-primed BMDMs transfected with control siRNA with a scrambled sequence or Drd1-Drd5-specific siRNA as indi-
cated, treated for 3 hr with DA and stimulated with nigericin.
(B) ELISA of IL-1b in supernatants from LPS-primed BMDMs of Drd1/ and Drd2/ mice treated for 3 hr with DA and stimulated with nigericin.
(C) Immunoblot analysis of IL-1b and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs fromDrd1/mice treated for 3 hr with DA and
then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1b (pro-IL-1b), caspase-1 (pro-caspase-1) and b-actin in lysates of those cells
(Input).
(D) Immunoblot analysis of IL-1b and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with various doses (above
lanes) of A-68930 and then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1b (pro-IL-1b) and caspase-1 (pro-caspase-1) in lysates of
those cells (Input).
(E) ELISA of IL-1b in supernatants from LPS-primed BMDMs of Drd1/ and Drd2/ mice treated for 3 hr with A-68930 and then stimulated with nigericin.
Data are means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S2.MSU, Alum, and ATP, similar to nigericin (Figures 1E and 1F),
suggesting that DA is a potent and broad inhibitor for NLRP3
inflammasome activation. Moreover, DA pretreatment had
minimal effect on poly (dA:dT) transfection-induced AIM2 in-
flammasome activation or Salmonella typhimurium (Salmonella)
infection-induced NLRC4 inflammasome activation (Figures
S1F–S1I). Taken together, these results demonstrate that DA
specifically inhibits NLRP3 inflammasome activation and subse-
quent IL-1b production.
DA Inhibits NLRP3 Inflammasome Activation via DRD1
Signaling
Next, we investigated the mechanisms underlying the inhibitory
activity of DA on NLRP3 inflammasome activation. DA exerts
its effects by binding to the activating receptors located on the
surface of cells. There are at least five subtypes of dopamine re-
ceptors identified, termed DRD1–DRD5, and all of them can be
detected in immune cells, including macrophages and dendritic
cells (McKenna et al., 2002; Meredith et al., 2005; Ricci et al.,
1999). To determine which receptor was involved in DA-induced64 Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc.NLRP3 inflammasome inhibition, these receptors were silenced
by small interfering RNA (siRNA) in BMDMs, respectively (Fig-
ures S2A and S2B). Knockdown of Drd1 in BMDMs significantly
suppressed the inhibitory effect of DA on inflammasome activa-
tion, while knockdown of Drd2, Drd3, or Drd4 in BMDMs had no
effect (Figure 2A). In addition, knockdown ofDrd5 in BMDMs had
a little bit of an effect on DA-induced inflammasome inhibition
(Figure 2A). These results suggest that DA inhibits NLRP3 inflam-
masome activation primary through DRD1. To further confirm
this, we tested the role of DA in Drd1/ cells. The results
showed that the inhibitory effect of DA on nigericin-induced IL-
1b secretion in BMDMs was inhibited completely or partially
when Drd1 was absent, depending on the doses of DA (Figures
2B and 2C). We also examined whether the agonist of DRD1
could inhibit inflammasome activation. First, we found that the
agonist of DRD1 A-68930 inhibited nigericin-induced IL-1b
secretion significantly, while it had no effect on cell viability, simi-
larly to DA (Figures 2D and S2C), and the agonists of DRD2,
DRD3, or DRD4 had mild or no effect on NLRP3 inflammasome
activation (Figure S2D). In addition, A-68930-induced NLRP3
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Figure 3. DRD1 Signaling Promotes
NLRP3 Ubiquitination and Degradation to
Inhibit NLRP3 Inflammasome
(A) Immunoblot analysis of NLRP3, AIM2, NLRC4,
ASC, Pro-caspase-1, and b-actin from LPS-
primed BMDMs treated for 3 hr with various doses
of DA.
(B) Immunoblot analysis of NLRP3, ASC, Pro-
caspase-1, and b-actin from LPS-primed BMDMs
treated for different time points of DA.
(C) Immunoblot analysis of NLRP3, ASC, Pro-
caspase-1, and b-actin from LPS-primed BMDMs
of Drd1/ mice treated for 3 hr of DA.
(D) LPS primed-BMDMs were treated with DA
(0.2 mM). Immunoblot analysis of K48-Ub and
K63-Ub proteins in cell lysates immunoprecipi-
tated with NLRP3 antibody.
(E) LPS primed-BMDMs from Drd1/ mice were
treated with DA (0.2 mM) for 1 hr. Immunoblot
analysis of K48-Ub protein in cell lysates immu-
noprecipitated with NLRP3 antibody.
(F) Immunoblot analysis of NLRP3 and b-actin in
cell lysates from LPS-primed BMDMs treated with
different doses of 3-MA for 30 min and then stim-
ulated with DA (0.2 mM) for 3 hr.
(G) Immunoblot analysis of NLRP3 and b-actin
in cell lysates from LPS-primed BMDMs
treated with different doses of MG132 for
30 min and then stimulated with DA (0.2 mM)
for 3 hr.
(H) Immunoblot analysis of LC3 and b-actin in cell lysates from LPS-primed BMDMs treated for different time points of DA (0.2 mM).
(I) Immunoblot analysis of LC3 and b-actin in cell lysates from LPS-primed BMDMs of Drd1/ mice treated with DA (0.2 mM) for 3 hr.
See also Figure S3.inflammasome inhibition was not affected by DRD1 deficiency
(Figure 2E).
Although our results showed that DA did not affect LPS-
induced TNF-a production when macrophages were treated
with DA after LPS (Figure 1D), previous results have shown
that DA can inhibit some inflammasome-independent cytokine
production, including TNF-a (Basu and Dasgupta, 2000). To
examine the role of DRD1 signaling in inflammasome-indepen-
dent cytokine production, we treated BMDMs with DA before
LPS and found that DA could suppress LPS-induced TNF-a
production, but the dose was higher than that needed for inflam-
masome inhibition (Figure S2E). In addition, the effect of DA on
LPS-induced TNF-a production were significantly impaired in
Drd2/ cells, while slightly reduced in Drd1/ cells, suggesting
that DA inhibits LPS-induced TNF-a production primarily via
DRD2 (Figure S2E). These results were consistent with a new
study in which they reported that Drd2/mice showed sponta-
neous inflammation in the brain and DRD2 can suppress the
transcription and production of proinflammatory cytokines,
including TNF-a (Shao et al., 2013). These results suggest that
DA signals through DRD1 to inhibit inflammasome activation
and signals through DRD2 to suppress the transcription proin-
flammatory cytokines.
DA and DRD1 Signaling Promote NLRP3 Ubiquitination
and Autophagy-Mediated Degradation
Next, we asked how DA and DRD1 signaling inhibit NLRP3
inflammasome activation. Interestingly, we found that DAtreatment induced NLRP3 degradation in a dose- and time-
dependent manner (Figures 3A and 3B). DA-induced protein
degradation was specific to NLRP3, because the expression of
AIM2, NLRC4, ASC, caspase-1, and pro-IL-1b were stable in
DA-treated BMDMs (Figures 3A and 3B). Similar to DA, treat-
ment with the DRD1 agonist A-68930 also induced NLRP3
degradation in BMDMs (Figures S3A and S3B). Further study
showed that DA-induced NLRP3 degradation was inhibited in
Drd1/macrophages (Figure 3C), suggesting that DA promotes
NLRP3 degradation via DRD1 signaling. Consistent with the
degradation of NLRP3, treatment with DA induced a K48-linked
polyubiquitination of NLRP3 in macrophages (Figure 3D). Impor-
tantly, DA-induced NLRP3 polyubiquitination was also impaired
in Drd1/ macrophages (Figure 3E).
We then asked whether proteasome or autophagy mediated
the degradation of ubiquitinated NLRP3 protein. Our results
showed that autophagy inhibitor 3-Methyladenine (3-MA) could
suppress DA-induced NLRP3 degradation, while proteasome in-
hibitor MG132 could not (Figures 3F and 3G), suggesting that
ubiquitinated NLRP3 is degraded via autophagy. Indeed, DA
treatment induced EGFP-NLRP3 to form big aggregates in
HEK293T cells (Figure S3C), which might explain why ubiquiti-
nated NLRP3 is degraded by autophagy, not by proteasome.
Consistent with this, DA treatment could induce autophagy in
BMDMs via DRD1 signaling (Figures 3H and 3I). Importantly,
DA-induced inflammasome inhibition could be rescued by auto-
phagy inhibitor 3-MA (Figure S3D). These results suggest that
autophagy mediates DA-induced NLRP3 degradation.Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc. 65
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Figure 4. DRD1 Signaling Promotes NLRP3 Ubiquitination and Degradation via cAMP
(A) ELISA of IL-1b in supernatants from LPS-primed BMDMs treated for 3 hr with forskolin and then stimulated with nigericin.
(B) Immunoblot analysis of IL-1b and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS-primed BMDMs treated for 3 hr with various doses (above
lanes) of forskolin and then stimulated with nigericin, and immunoblot analysis of the precursors of IL-1b (pro-IL-1b) and caspase-1 (pro-caspase-1) in lysates of
those cells (Input).
(C) Immunoblot analysis of NLRP3 and b-actin in cell lysates from LPS-primed BMDMs treated for different time points of forskolin (100 mM).
(D) ELISA of IL-1b in supernatants from LPS primed-BMDMs treated with different doses of KH7 for 30 min before 3 hr DA treatment and then stimulated with
nigericin.
(E) Immunoblot analysis of IL-1b and cleaved caspase-1 (p20) in culture supernatants (SN) of LPS primed-BMDMs treated with KH7 (5 mM) for 30 min before 3 hr
DA treatment and then stimulated with nigericin.
(F) Immunoblot analysis of NLRP3 and b-actin in cell lysates from LPS primed-BMDMs treated with different doses of KH7 for 30 min before 3 hr DA treatment.
(G) LPS primed-BMDMs were treated with KH7 (5 mM) for 30 min before 1 hr DA treatment. Immunoblot analysis of K48-Ub protein from the cell lysates
immunoprecipitated with anti-NLRP3 antibody.
(H) Lysates from LPS primed-BMDMs were treated with different doses of cAMP for 30 min. Immunoblot analysis of K48-Ub protein from the cell lysates
immunoprecipitated with anti-NLRP3 antibody.
(I) LPS primed-BMDMs were treated with DA (0.2 mM) for 1 hr. Immunoblot analysis of cAMP and NLRP3 proteins from the cell lysates immunoprecipitated with
anti-NLRP3 antibody.
Data are means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S4.DRD1 Signaling Induces NLRP3Ubiquitination via Cyclic
AMP-Dependent Manner
We further investigated how DRD1 signaling promotes NLRP3
ubiquitination. DRD1 signaling can stimulate the activity of ad-
enylate cyclase and the production of cyclic AMP (cAMP), which
is a second messenger and is important in many biological pro-
cesses (Beaulieu et al., 2004; Nishi et al., 2011). Recently, cAMP
has been proposed to negatively regulate NLRP3 inflammasome66 Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc.activation (Lee et al., 2012), so we examined the role of cAMP
in DA-induced inflammasome inhibition. We found that the in-
crease of the cAMP levels with adenylate cyclase (ADCY) acti-
vator forskolin inhibited NLRP3 inflammasome activation with a
dose-dependent manner (Figures 4A and 4B), consistent with
a previous report (Lee et al., 2012). Furthermore, forskolin treat-
ment promoted NLRP3 degradation and ubiquitination in mac-
rophages (Figures 4C and S4A), similar with DA treatment.
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Figure 5. DRD1 Signaling Promotes
NLRP3 Ubiquitination through E3 Ligase
MARCH7
(A) List of E3 ligase proteins for top peptide hits
identified in mass spectrometry study.
(B) Immunoblot analysis of NLRP3 and b-actin in
cell lysates from LPS-primed DA-treated BMDMs
transfected with siRNA against March7.
(C) BMDMs were transfected with siRNA against
March7. After 48 hr, the cells were primed with LPS
and then stimulated with DA (0.2 mM) for 1 hr.
Immunoblot analysis of K48-Ub protein from the
cell lysates immunoprecipitated with anti-NLRP3
antibody.
(D) ELISA of IL-1b in supernatants from LPS-
primed DA and nigericin-treated BMDMs trans-
fected with siRNA against March7
(E) Flag-tagged NLRP3 constructs and MARCH7
construct were cotransfected in HEK293T cells.
Immunoblot analysis of MARCH7 and Flag pro-
teins in cell lysates immunoprecipitated with anti-
Flag antibody. EV, empty vector.
(F) LPS primed-BMDMs were treated with KH7
(5 mM) for 30 min before 1 hr DA treatment. Immu-
noblot analysis of MARCH7 protein in cell lysates
immunoprecipitated with anti-MARCH7 antibody.
(G and H) Flag-tagged NLRP3 construct and
MARCH7constructwerecotransfected inHEK293T
cells. Immunoblot analysis of K48-Ub protein in cell
lysates immunoprecipitatedwith anti-Flagantibody.
Data are means ± SEM, *p < 0.05, ***p < 0.001.
See also Figure S5.Importantly, DA-induced NLRP3 inflammasome inhibition could
be blocked by KH7, an ADCY inhibitor (Figures 4D and 4E), sug-
gesting that DA-induced NLRP3 inflammasome inhibition is
cAMP-dependent. Consistent with this, DA-induced NLRP3
degradation and ubiquitination could also be inhibited by KH7
(Figures 4F and 4G). Actually, cAMP also could promote
NLRP3 ubiquitination in the lysates of macrophages (Figure 4H).
These results indicate that the increase of cAMP in cells can pro-
mote NLRP3 ubiquitination and degradation.
Protein kinase A (PKA) and exchange protein activated by
cAMP (EPAC) are the two known sensors for intracellular
cAMP, so we tested whether they were involved in DA-induced
NLRP3 inflammasome inhibition (Gloerich and Bos, 2010). The
results showed that inhibition of PKA with H89 did not affect
DA-induced NLRP3 inflammasome inhibition or DA-promoted
NLRP3 degradation (Figures S4B and S4C). In addition, EPAC
agonist also had no effect on NLRP3 inflammasome activation
or NLRP3 degradation (Figures S4D and S4E). These results
suggest that PKA and EPAC are not the downstream of cAMP
to promote NLRP3 ubiquitination. Actually, when NLRP3 were
immunoprecipitated and the precipitates were examined with
anti-cAMP antibody, a band with the same size of NLRP3 could
be detected with anti-cAMP antibody (Figure 4I), suggesting that
NLRP3 can directly interact with cAMP, possibly by covalent
linkage. Importantly, DA treatment promoted the interaction be-
tween cAMP and NLRP3 significantly (Figure 4I). These results
indicate that DA-induced cAMP promotes NLRP3 ubiquitination
and degradation via binding with NLRP3.We then examined the role of cAMP in DA-induced auto-
phagy. The results showed that KH7 could inhibit DA-induced
autophagy, while forskolin could promote autophagy (Figures
S4F and S4G), similar with DA, suggesting that DA-induced
autophagy is cAMP-dependent. Similarly, DA-induced auto-
phagy was PKA- and EPAC-independent (Figures S4H and
S4I), suggesting that cAMP promotes autophagy without the
involvement of its known downstream signaling. Importantly,
DA-induced NLRP3 aggregation was inhibited by KH7 (Fig-
ure S4J), suggesting that cAMP promotes the formation of
NLRP3 aggregates, which could trigger autophagy for its
degradation.
Taken together, these results suggest that the binding of
cAMPwith NLRP3 promotes its ubiquitination and then the ubiq-
uitinated NLRP3 forms aggregates, which are targeted for
degradation by autophagy.
DRD1 Signaling Promotes NLRP3 Ubiquitination via
E3 Ubiquitin Ligase MARCH7
To identify the E3 ligase that is responsible for DA-induced
NLRP3 ubiquitination and degradation, we used mass spec-
trometry (MS) to identify the E3 ligases associated with NLRP3
and found that E3 ligases CHIP, MARCH7, and UBR5 had the
highest number of matched peptides identified by MS in the pre-
cipitates (Figure 5A). Further studies showed that knockdown of
Chip or Ubr5 by using siRNA did not affect DA-induced NLRP3
degradation in BMDMs (Figures S5A–S5C). However, knock-
down of March7 could rescue DA-induced NLRP3 degradationCell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc. 67
in BMDMs (Figures 5B and S5A). Moreover, DA-induced NLRP3
ubiquitination was also impaired when March7 was silenced
(Figure 5C). Consistent with this, the effect of DA on IL-1b secre-
tion depended on MARCH7 (Figure 5D). In addition, forskolin-
induced NLRP3 degradation, ubiquitination, and inflammasome
inhibition were also rescued by March7 knockdown (Figures
S5D–S5F). These results suggest the importance of E3 ligase
MARCH7 in DRD1 signaling and cAMP-induced NLRP3 ubiquiti-
nation and inflammasome inhibition.
We further investigated howMARCH7 promoted NLRP3 ubiq-
uitination. First, we found that overexpressed MARCH7 not only
interacted with full-length NLRP3, but also interacted with
NACHT or LRR domain, but not with PYD domain, in HEK293T
cells (Figure 5E). Second, DA treatment could promote the
endogenous interaction between NLRP3 and MARCH7 in
BMDMs (Figure 5F), and this effect also depended on cAMP
because KH7 could inhibit the interaction between NLRP3 and
MARCH7 (Figure 5F). Importantly, overexpressed MARCH7
could promote NLRP3 ubiquitination and degradation in
HEK293T cells (Figure 5G). Further studies showed that
MARCH7 overexpression could promote the ubiquitination and
degradation of LRR domain strongly, but could not induce the
degradation of NACHT domain, although MARCH7 had some
effect to enhance its ubiquitination (Figure 5H). These results
suggest that LRR domain is the key region of NLRP3 for
MARCH7-mediated ubiquitination and degradation.
DRD1 Signaling Prevents MPTP-Induced
Neuroinflammation via Suppression of NLRP3
Inflammasome
Abundant evidence implicates that immune system abnormal-
ities and neuroinflammation are sustaining and exacerbating
reasons for the loss of the dopaminergic neurons and DA
deficiency (Brochard et al., 2009; Perry, 2012; Rodrigues et al.,
2013; Shao et al., 2013). NLRP3 inflammasome has been re-
ported to be involved in the progression of several human
diseases (Davis et al., 2011; Martinon et al., 2009). NLRP3 in-
flammasome can be activated by aggregated a-Synuclein,
which has been suggested directly linked to the pathogenesis
of PD (Codolo et al., 2013). To determine the role of NLRP3 in-
flammasome-driven neuroinflammation in the neurodegenera-
tion of nigral dopaminergic neurons, Nlrp3/mice were treated
with neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). The data showed that Nlrp3/ mice were resistant to
MPTP-induced loss of nigral dopaminergic neurons compared
with their wild-type mice (Figures S6A and S6B). This difference
was associated with reduced IL-1b and IL-18 production in
serum and impaired caspase-1 activation in brain tissue (Figures
S6C and S6D), suggesting that dysregulation of NLRP3 inflam-
masome contributes to the development of MPTP-induced
loss of nigral dopaminergic neurons.
We then want to know whether DA and DRD1 signaling can
prevent MPTP-induced neuroinflammation and loss of neurons.
In brain, the activated microglias and astrocytes have been
regarded as important contributors for the progression of PD
(Lucin and Wyss-Coray, 2009). Both microglias and astrocytes
express NLRP3 and secrete IL-1b via NLRP3 inflammasome-
dependent manner (Alfonso-Loeches et al., 2014; Halle et al.,68 Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc.2008). We first checked whether DA could inhibit inflammasome
activation in microglias and astrocytes. The results showed that
DA treatment could inhibit nigericin-induced IL-1b production in
both microglias and astrocytes, and the inhibitory effects of DA
were impaired in Drd1/ cells (Figures 6A and 6B). Moreover,
DRD1 signaling also induced NLRP3 degradation in microglias
and astrocytes (Figures 6C and 6D). These results suggest that
DA and DRD1 signaling can promote NLRP3 degradation to
inhibit inflammasome activation in microglias and astrocytes.
To further study the in vivo relevance of inflammasome inhibition
by DA,Drd1/mice were administrated withMPTP and the loss
of dopaminergic neurons was examined. The results showed
that Drd1/ mice displayed more severe loss of nigral dopami-
nergic neurons compared with wild-type mice when treated with
MPTP (Figures 6E and 6F). Consistent with this, Drd1/ mice
also showed more inflammasome activation by analyzing IL-1b
and IL-18 production or caspase-1 activation (Figures 6G and
6H). However, Drd1/Nlrp3/ mice did not show more severe
loss of dopaminergic neurons, IL-1b and IL-18 production, or
caspase-1 activation compared with Drd1/mice (Figures
S6A–S6D). Moreover, MPTP-treated Drd1/ mice showed
more NLRP3 expression and less NLRP3 ubiquitination in the
brain tissue compared with Drd1+/+ mice, suggesting that
DRD1 signaling might promote NLRP3 ubiquitination in MPTP-
induced neuroinflammation (Figure 6I). These results suggest
that DRD1 signaling can prevent neuroinflammation via inhibition
of NLRP3 inflammasome by promoting NLRP3 ubiquitination
in vivo.
To further study the protective role of DRD1 signaling in neuro-
inflammation, Drd1+/+ or Drd1/ mice were treated with DRD1
agonist A-68930 before MPTP treatment. A-68930 administra-
tion resulted in a remarkable reduction of dopaminergic neuron
damage, IL-1b or IL-18 production, and caspase-1 activation
in Drd1+/+ mice, but not in Drd1/ mice (Figures 6E–6H), indi-
cating that activation of DRD1 signaling can protect MPTP-
induced inflammasome activation and dopaminergic neuron
damage in vivo.
DA and DRD1 Signaling Mitigate LPS-Induced Systemic
Inflammation and MSU-Induced Peritoneal
Inflammation by Inhibition of NLRP3 Inflammasome
In addition to function as neurotransmitter in the brain, DA also
functions as a local chemical messenger in several periphery
parts of the body, including blood, intestine, and kidney (Beau-
lieu andGainetdinov, 2011). Importantly, DA is a ‘‘first line’’ agent
for septic shock as a vasopressor over the past two decades (De
Backer et al., 2010). Because septic shock is an inflammatory
disorder, we askedwhether DA could suppress the inflammatory
responses via inhibition of NLRP3 inflammasome in septic
shock. The Nlrp3+/+ or Nlrp3/ mice were treated with DA
when challenged with LPS to induce septic shock, and the re-
sults showed that DA treatment resulted in significant reduction
of serum IL-1b or IL-18 production in Nlrp3+/+ mice but had no
effect inNlrp3/mice (Figures 7A and 7B). In addition, DA treat-
ment had only mild effect on serum TNF-a production, which
was inflammasome-independent (Figure 7C). These results sug-
gest that DA can inhibit LPS-induced NLRP3 inflammasome
activation in vivo.
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Figure 6. DRD1 Signaling Prevents Neuroinflammation via Suppression of NLRP3 Inflammasome
(A) ELISA of IL-1b in supernatants from LPS-primed microglias of Drd1+/+ or Drd1/ mice treated with DA (0.2 mM) for 3 hr and stimulated with nigericin.
(B) ELISA of IL-1b in supernatants from LPS-primed astrocytes of Drd1+/+ or Drd1/ mice treated with DA (0.2 mM) for 3 hr and stimulated with nigericin.
(C) Immunoblot analysis of NLRP3 and b-actin in cell lysates from LPS-primed microglias of Drd1+/+ or Drd1/ mice treated with DA (0.2 mM) for 3 hr.
(D) Immunoblot analysis of NLRP3 and b-actin in cell lysates from LPS-primed astrocytes of Drd1+/+ or Drd1/ mice treated with DA (0.2 mM) for 3 hr.
(E) Immunofluorescent histochemical staining for tyrosine hydroxylase (TH) on the ventral mesencephalon ofDrd1+/+ orDrd1/mice administrated withMPTP or
MPTP plus A-68930. Scale bar represents 500 mM.
(F) Quantitative data of TH expression on the ventral mesencephalon of Drd1+/+ or Drd1/ mice administrated with MPTP or MPTP plus A-68930.
(G) ELISA of IL-1b and IL-18 in serum of Drd1+/+ or Drd1/ mice administrated with MPTP or MPTP plus A-68930.
(H) Immunoblot analysis of caspase-1 cleavage (p20), pro-caspase-1, and b-actin of Drd1+/+ or Drd1/mice administrated with MPTP or MPTP plus A-68930.
(I) Drd1+/+ and Drd1/ mice were treated with MPTP. Immunoblot analysis of the lysates of brain tissue immunoprecipitated with anti-NLRP3 antibody.
Data are means ± SEM, **p < 0.01, ***p < 0.001.
See also Figure S6.To determine whether DA can inhibit LPS-induced systemic
inflammation via DRD1 signaling, Drd1+/+ and Drd1/ mice
were treated with LPS, and the results showed that LPS
induced more serum IL-1b and IL-18 production, but compara-
ble TNF-a production in Drd1/ mice (Figures 7D–7F). More-
over, DA treatment could suppress LPS-induced serum IL-1b
and IL-18 production in Drd1+/+ mice, but had little effect in
Drd1/ mice (Figures 7D and 7E). Importantly, Drd1 deletion
in Nlrp3/ mice could not enhance LPS injection-induced
serum IL-1b and IL-18 production (Figures 7G and 7H). Consis-
tent with DRD1 signaling-induced inhibition of NLRP3 inflamma-
some in vivo, DA treatment in vivo also could induce NLRP3ubiquitination and degradation in peritoneal macrophage of
Drd1+/+ mice, but not in Drd1/ mice (Figures S7A and S7B).
In addition, treatment with autophagy inhibitor 3-MA to inhibit
the degradation of NLRP3 could impair DA-induced inflam-
masome inhibition in LPS-treated mice (Figure S7C). These
results indicate that DRD1 signaling can inhibit LPS-induced
systemic inflammation via suppression of NLRP3 inflamma-
some activation.
To further study the protective effect of DRD1 signaling in pe-
riphery inflammation, we examined whether DRD1 signaling
could suppress MSU-induced peritoneal inflammation, which
is NLRP3 inflammasome-dependent (Martinon et al., 2006).Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc. 69
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Figure 7. DRD1 Signaling Prevents LPS-
Induced Systemic Inflammation and
MSU-Induced Peritoneal Inflammation via
Suppression of NLRP3 Inflammasome
(A–C) ELISA of IL-1b (A), IL-18 (B), and TNF-a (C) in
serum ofNlrp3+/+ orNlrp3/mice intraperitoneally
injected with LPS (20mg/kg of body weight) with or
without DA (50 mg/kg of body weight).
(D–F) ELISA of IL-1b (D), IL-18 (E), and TNF-a (F) in
serum of Drd1+/+ or Drd1/ mice intraperitoneally
injected with LPS (20mg/kg of body weight) with or
without DA (50 mg/kg of body weight).
(G and H) ELISA of IL-1b (G) and IL-18 (H) in serum
of Nlrp3/ mice or Nlrp3/Drd1/ mice intra-
peritoneally injected with LPS (20 mg/kg of body
weight).
Data are means ± SEM, *p < 0.05, **p < 0.01, ***p <
0.001. NS p > 0.05.
See also Figure S7.The result showed thatMSU could inducemore IL-1b production
and recruit more neutrophils in peritoneal cavity of Drd1/mice
(Figures S7D and S7E). Moreover, DA treatment could inhibit
MSU-induced IL-1b production and neutrophil recruitment in
Drd1+/+ mice, but not in Drd1/ mice (Figures S7D and S7E).
These results indicate that DRD1 signaling has a negative role
inMSU-induced NLRP3 inflammasome activation and peritoneal
inflammation in vivo.
DISCUSSION
Increasing evidence has shown that the immune system can be
influenced by the nervous system and neurotransmitters (Olofs-
son et al., 2012; Tracey, 2009). DA not only functions as a neuro-
transmitter in the brain, but also functions as a local chemical
messenger in several periphery parts of the body. A substantial
amount of dopamine circulates in the bloodstream, but its func-
tions are not entirely clear. Here, our results demonstrate that DA
is an endogenous inhibitor of NLRP3 inflammasome activation,
suggesting that DA is a potential antiinflammatory chemical, in
addition to a neurotransmitter. The effect of dopamine and its ag-
onists on immune responses including proliferation and cytokine
production has been reported. Bergquist et al. (1994) reported
that either DA or L-dihydroxyphenylalanine, a precursor of DA,
resulted in a dose-dependent inhibition of lymphocyte prolifera-
tion and differentiation. Josefsson et al. (1996) reported that DA
inhibited the ConA- or LPS-induced proliferation and cytokine
production of lymphocytes. Ghosh et al. (2003) reported that
DA suppressed anti-CD3-mediated proliferation and cytokine
production in activated T cells. Thus, our results and previous70 Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc.studies suggest that DA might play an
important role in the communication be-
tween nervous system and immune
system.
DA exerts its effects by binding to the
activating receptors located on the sur-
face of cells. There are at least five sub-
types of dopamine receptors that have
been identified, termed DRD1–DRD5,and most of them can be detected in immune cells, including
macrophages and dendritic cells (McKenna et al., 2002; Mere-
dith et al., 2005; Ricci et al., 1999). Here, our results show that
DRD1 plays a primary role and DRD5 plays a minor role, while
DRD2, DRD3, and DRD4 have no roles in DA-induced NLRP3 in-
flammasome inhibition. The different roles of DA receptors could
be explained by their different downstream signalings. Activation
of D1-like receptors (DRD1 and DRD5) increases intracellular
cAMP levels, while activation of D2-like receptors (DRD2,
DRD3, DRD4) decreases intracellular cAMP levels (Missale
et al., 1998). Consistent with this, our results demonstrate that
cAMP played a critical role in DA-induced inflammasome inhibi-
tion. Taken together, our results indicate that DA can negatively
regulate NLRP3 inflammasome activation via DRD1 signaling
and suggest that DRD1 might be a potential target for treatment
of inflammatory diseases.
NLRP3 inflammasome-mediated IL-1b production is a two-
step process: a primary signal that induces pro-IL-1b and
NLRP3 synthesis and a secondary signal that activates the
inflammasome and the subsequent caspase-1 processing
(Bauernfeind et al., 2011). NLRP3 protein expression levels
have been shown to be a limiting step in inflammasome activa-
tion (Bauernfeind et al., 2009; Franchi et al., 2009). Here, we
demonstrate that DA can induce the degradation of NLRP3
protein to inhibit NLRP3 inflammasome and support the recent
findings that NLRP3 ubiquitination might play an important role
in the regulation of inflammasome activation (Juliana et al.,
2012; Py et al., 2013).
Increasing evidence imply that immune dysregulation and
neuroinflammation are sustaining and exacerbating reasons for
the loss of the dopaminergic neurons in PD (Brochard et al.,
2009; Perry, 2012; Rodrigues et al., 2013; Shao et al., 2013),
although the precise mechanisms causing uncontrolled inflam-
mation remain unclear. In this study, we demonstrate that
NLRP3 inflammasome is involved in the MPTP-induced loss of
the dopaminergic neurons. Moreover, our results show that DA
and DRD1 signaling has a protective role for MPTP-induced
loss of dopaminergic neurons by suppressing NLRP3 inflamma-
some activation. Although DRD2was not involved in DA-induced
NLRP3 inflammasome inhibition, a previous report has shown
that DRD2 signaling also has a protective role in MPTP-induced
loss of the dopaminergic neurons (Shao et al., 2013). It seems
DRD2 signaling can affect the transcription of proinflammatory
cytokines, including pro-IL-1b, TNF-a, et al., according to Shao
et al. (2013). Consistent with this, our study found that DRD2
signaling played a primary role in the inhibitory effect of DA on
LPS-induced TNF-a production, while DRD1 only had a minor
role. In addition, Drd2/ mice show spontaneous inflammation
in the brain, while Drd1/ mice do not (Shao et al., 2013). This
suggests that DRD1 only functions to suppress inflammation in
‘‘stressed’’ condition. These results indicate that DRD1 and
DRD2 signaling exert a different role in the suppression of inflam-
mation: DRD2 signaling inhibits the transcription proinflamma-
tory cytokines, while DRD1 signaling inhibits the processing
and secretion of IL-1b and IL-18 via suppressing inflammasome.
DA is not only an important neurotransmitter in the brain, but
also functions as a local chemical messenger in several periph-
ery parts of the body, including blood, intestine, and kidney
(Beaulieu and Gainetdinov, 2011). Our results showed that DA
treatment in mice suppressed LPS-induced inflammasome-
dependent cytokine production, such as IL-1b and IL-18. More
importantly, Drd1/ mice are susceptible to LPS-induced sys-
temic inflammation. In addition, our results also showed that
DA and DRD1 signaling could suppressMSU-induced IL-1b pro-
duction and neutrophil infiltration in peritoneal cavity. These re-
sults suggest that DA and DRD1 signaling can inhibit systemic
or periphery inflammation by inhibition of NLRP3 inflammasome.
Although our results indicate that DA and DRD1 signaling can
control both central and periphery inflammation in vivo by inhibi-
tion of NLRP3 inflammasome, the DA concentration required for
inflammasome inhibition in vitro exceeds the reported physiolog-
ical concentration of DA (Basu et al., 2001; Chakroborty et al.,
2008). To address this issue, we provided results showing that
multiple treatments with low dose of DA could inhibit inflamma-
some activation, while the single treatment with high dose (the
same dose with the total dose of multiple treatments) could
not. Although this is not enough to prove that the physiological
dose of DA can inhibit inflammasome activation, it clearly shows
that the instability of DA is an important reason for the require-
ment of a high dose of DA for inflammasome inhibition. In order
to further find out whether the physiological dose of DA can
inhibit inflammasome activation, we treated macrophages with
physiological dose of DA in the presence of MAO and COMT in-
hibitors and found that low dose of DA could inhibit inflamma-
some activation in this condition. These results together suggest
that the persistent treatment with physiological dose of DA can
inhibit inflammasome activation in vitro. For the in vivo, although
the concentration of DA is controlled by MAO and COMT, thedopaminergic neurons can produce DA continuously so the DA
levels could be maintained. In addition, we should note that it
is hard to measure the levels of DA in vivo because DA is broken
very fast. The reported physiological concentration of DA might
be much lower than the actual concentration.
Collectively, our results demonstrate that DA and DRD1
signaling can suppress NLRP3 inflammasome activation and
identify an endogenous regulatorymechanism for NLRP3 inflam-
masome-related inflammation. Our results also demonstrate
that DA and DRD1 signaling can prevent neurotoxin-induced
neuroinflammation, LPS-induced systemic inflammation, and
MSU-induced peritoneal inflammation in vivo, suggesting that
DA is a restrictor for the development of inflammatory diseases,
and DRD1 is a potential target for the treatment for NLRP3-
driven inflammatory diseases.
EXPERIMENTAL PROCEDURES
Mice
Nlrp3/, Drd1/, and Drd2/mice were described previously (Drago et al.,
1994; Kelly et al., 1997; Martinon et al., 2006).Drd1/ andNlrp3/mice were
crossed to generate Drd1/Nlrp3/ mice. All animal experiments were
approved by the Ethics Committee of University of Science and Technology
of China.
Cell Preparation and Stimulation
Bone-marrow macrophages were isolated and cultured as described (Yan
et al., 2013). Astrocytes were prepared from the striatum of mice at P0, as
described (Shao et al., 2013). Microglias were prepared from neonatal mice
(age 1–3 days) as described previously (Saura et al., 2003).
For inducing inflammasome activation, 5 3 105 cells were plated in 12-well
plate overnight and the medium were changed to opti-MEM in the following
morning and then the cells were primed with ultra-LPS (500 ng/ml) for 3 hr.
After that, the cells were stimulated as described (Yan et al., 2013).
Immunofluorescence
Confocal microscopy analyses were carried out using a Zeiss LSM700. Frozen
sections were incubated with the primary antibody for tyrosine hydroxylase
followed by incubation with secondary antibody conjugated with Alexa543.
Sections were imaged using a cooled CCD (DP72, Olympus) on a microscope
(BX53, Olympus).
siRNA-Mediated Gene Silences in BMDMs
BMDMs were plated in 12-well plates (4 3 105 cells per well) and then were
transfected with 50 nM siRNA using Lipofectamine RNAiMAX (Invitrogen) ac-
cording to the manufacturer’s guidelines.
MPTP-Induced Neuroinflammation In Vivo
Adult mice (12 weeks) were intraperitoneally given with 20 mg/kg MPTP five
times at 2 hr intervals. After 24 hr, the serum samples were collected for ELISA
and the brains were dissected and processed for immunohistochemistry or
immunoblotting analysis.
LPS-Induced Systemic Inflammation In Vivo
To induce in vivo cytokine secretion, adult mice (12 weeks) were injected intra-
peritoneally with LPS (20 mg/kg) alone or LPS plus DA (50 mg/kg). After 4 hr,
the serum samples were collected and the cytokines were measured by
ELISA.
Statistical Analyses
All values are expressed as the mean ± SEM. Statistical analysis were per-
formed with the t test for two groups or one-way ANOVA (GraphPad Software)
for multiple groups. P values < 0.05 were considered significant.
See Extended Experimental Procedures for more information.Cell 160, 62–73, January 15, 2015 ª2015 Elsevier Inc. 71
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